Last reviewed · How we verify
Terlipressin Injectable Product
Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor.
Terlipressin is a synthetic analogue of vasopressin that acts as a potent vasoconstrictor. Used for Hemorrhagic shock, Hepatorenal syndrome.
At a glance
| Generic name | Terlipressin Injectable Product |
|---|---|
| Also known as | Novapressin |
| Sponsor | Aga Khan University |
| Drug class | Vasopressin analogue |
| Target | V2 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating V2 receptors in the kidneys, leading to water reabsorption and increased blood pressure. This effect is particularly useful in treating certain types of shock and bleeding disorders.
Approved indications
- Hemorrhagic shock
- Hepatorenal syndrome
Common side effects
- Hypotension
- Nausea
- Headache
Key clinical trials
- Efficacy and Safety of Continuous Infusion of Terlipressin vs Bolus Terlipressin in ACLF Patients With Acute Esophageal Variceal Bleed (PHASE2, PHASE3)
- Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis (NA)
- Clinical Trial Comparing Noradrenaline (NA) Plus Placebo Versus Noradrenaline Plus Terlipressin (TP) in Septic Shock (PHASE3)
- Methods Decreasing Bleeding in Open Myomectomy (PHASE4)
- Methylene Blue Versus Vasopressin Analogue for Treatment of Septic Shock in Preterm Neonate (PHASE2)
- Terlipressin Infusion in Variceal Hemorrhage (PHASE3)
- Terlipressin Administration in Patients Undergoing Major Liver Resection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Terlipressin Injectable Product CI brief — competitive landscape report
- Terlipressin Injectable Product updates RSS · CI watch RSS
- Aga Khan University portfolio CI